


REMARKS

The amendment is submitted to insert reference to the PCT application, to remove multiple dependency from the claims and to conform the claims to the American practice.

Respectfully submitted,
BIERMAN, MUSERLIAN AND LUCAS


Charles A. Muserlian, #19,683
Attorney for Applicant(s)
Tel. # (212) 661-8000

CAM:sd

Enclosures: Marked-Up Version of Specification and Claims
Return Receipt Postcard

10089287.032602

Cross-linked copolymers based on**non cross-linked polycarboxylic copolymers**

—This application is a 371 of PCT/FR00/02731 filed October 3, 2000.—

The invention relates to cross-linked copolymers based on non cross-linked polycarboxylic copolymers, said non cross-linked copolymers containing at least one polysaccharide. The invention also relates to a process for the preparation of these copolymers and their use in particular as a support in pharmaceutical compositions.

- 5 A subject of the invention is therefore cross-linked copolymers based on non cross-linked polycarboxylic copolymers and a cross-linking agent comprising at least two amine functions; each non cross-linked polycarboxylic copolymer comprises at least one non cross-linked polysaccharide linked by a covalent bond to at least one other non saccharidic non cross-linked polymer. Finally at least one of the polysaccharides and
10 non saccharidic polymers constituting the same non cross-linked copolymer, is polycarboxylic.

In Application WO98/08897, the Applicant claimed cross-linked copolymers, based on non cross-linked polycarboxylic polymers, said copolymers containing at least one polycarboxylic polysaccharide. Thus, a copolymer according to the aforementioned
15 international Application contains at least one polycarboxylic polysaccharide and at least one other polycarboxylic polymer which is not a polysaccharide (lines 16-18 of Page 1 of Application WO98/08897). However, the process which consists of mixing the polycarboxylic polymers of the two types (polysaccharidic and non polysaccharidic), in aqueous solution does not exclude the existence, in the final cross-linked copolymer,
20 of heterogeneities resulting from cross-linking reactions either between polysaccharides only, or between non polysaccharidic carboxylic polymers only.

The present Application therefore proposes to resolve this problem by firstly preparing copolymers of the two starting types (polycarboxylic polysaccharide polymer on the one hand and non-saccharidic polycarboxylic polymer on the other hand), then cross-linking
25 the copolymers thus obtained; this allows possible heterogeneities to be excluded insofar as a covalent bond exists before the cross-linking reaction. The invention therefore proposes new cross-linked copolymers based on non cross-linked polycarboxylic copolymers.

209220 032607

CLAIMS

1- ^{A_c} ~~cross-linked copolymers based on~~ ^{at least one} non cross-linked polycarboxylic copolymers and a cross-linking agent ^{having} ~~comprising~~ at least two amine functions,

each non cross-linked polycarboxylic copolymer comprising at least one non cross-linked polysaccharide linked by a covalent bond to at least one other non-saccharidic non-cross-linked polymer, and

at least one of the non saccharidic polysaccharides and polymers, ^{having} ~~constituting~~ the same non cross-linked copolymer, is polycarboxylic.

2- ^{A_c} ~~Copolymers according to claim 1,~~ ^{wherein} ~~characterized in that~~ the polysaccharide is non-polycarboxylic.

10 3- ^{A_c} ~~Copolymers according to one of claims 1 to 2,~~ ^{wherein} ~~characterized in that~~ the non polycarboxylic polysaccharide is ^{selected} ~~chosen~~ from ^{The group consisting of} agarose, agaropectin, amylose, amylopectin, arabinogalactan, carrageenans, cellulose, ~~or~~ methylcellulose, chitosan, dextran, keratan sulfate, fucans and fucoidans, tragacanth, arabic, locust bean, ~~and~~ guar gums, ~~or~~ pullulan.

15 4- ^{A_c} ~~Copolymers according to claim 1,~~ ^{wherein} ~~characterized in that~~ the polysaccharide is polycarboxylic.

5- ^{A_c} ~~Copolymers according to one of claims 4 or 4,~~ ^{wherein} ~~characterized in that~~ the polycarboxylic polysaccharide is ^{selected} ~~chosen~~ from the ^{group consisting of} glycosaminoglycans, pectinic ~~and~~ alginic acid.

20 6- ^{A_c} ~~Copolymers according to one of claims 4 or 5,~~ ^{wherein} ~~characterized in that~~ the polycarboxylic polysaccharide is a glycosaminoglycane ^{selected} ~~chosen~~ from hyaluronic acid, chondroitin sulfate, heparin, dermatan sulfate and heparan sulfate.

7- ^{A_c} ~~Copolymers according to claim 1 to 6,~~ ^{wherein} ~~characterized in that~~ the non saccharidic polymer is non polycarboxylic.

10089287.032607
20926078268007

8-^{Ac} Copolymers ~~according to one of claims 1 to 7, characterized in that~~ ^{wherein} the non polycarboxylic non saccharidic polymer is ~~chosen~~ ^{selected} from ~~poly(vinyl acetate), poly(vinyl alcohol), poly(acrylic esters), poly(methacrylic esters), poly(methacrylamides) and poly(acrylamides).~~ ^{the group consisting of}

5 9-^{Ac} Copolymers ~~according to any one of claims 1 to 6, characterized in that~~ ^{wherein} the non saccharidic polymer is polycarboxylic.

10-^{Ac} Copolymers ~~according to any one of claims 1 to 6 or 9, characterized in that~~ ^{wherein} the non saccharidic polymer is a polycarboxylic acrylic polymer.

10 11-^{Ac} Copolymers ~~according to claim 10, characterized in that~~ ^{wherein} the polycarboxylic acrylic polymer is poly(acrylic acid) or poly(methacrylic acid).

12-^{Ac} Copolymers ~~according to any one of claims 1 to 11, in which the cross-linking agent is chosen from~~ ^{wherein} ~~diamines, natural or synthetic amino acids or polyamines, and preferentially diamines.~~ ^{selected} ^{the group consisting of} 5 ^{and}

13-^{Ac} Copolymers ~~according to claim 12 in which~~ ^{wherein} the cross-linking agent is a diamine.

15 14-^{Ac} Copolymers ~~according to one of claims 1 to 13, characterized in that~~ ^{wherein} the polysaccharide is degradable by the microbial flora of the colon.

15-^{Ac} Copolymers ~~according to claim 14, characterized in that~~ ^{wherein} the polysaccharide is ~~chosen~~ ^{selected} from ~~chondroitin sulfate, hyaluronic acid, pectinic acid, heparin, dextran, chitosan, amylose, pectin, alginates or xanthan.~~ ^{the group consisting of} 4 ^{and}

20 16-^{Ac} Copolymers ~~according to any one of claims 14 to 15, characterized in that~~ ^{wherein} the polysaccharide is chondroitin sulfate, the other said non saccharidic polymer is poly(acrylic acid) or poly(methacrylic acid), and the cross-linking agent is hexanediamine.

25 17-^{Ac} Process for the preparation of cross-linked copolymers ~~according to any one of claims 1 to 16, characterized in that~~ ^{1. comprising reacting} said non cross-linked polycarboxylic copolymers ~~are reacted~~ in an aqueous medium, in the presence of an activator and of said cross-linking agent.

10089287-032602

The
18- ~~Process according to claim 17,~~ *when* ~~in which the activator is chosen from carbodiimides,~~ *selected* ~~quinoline derivatives and mixed anhydrides.~~ *the group consists of*

A
19- ~~Process for the preparation of non cross-linked copolymers according to claim 1,~~ *of* ~~characterized in that the monomer of the non saccharidic polymer is grafted onto the~~ *comparing grafting*
5 polysaccharide in an aqueous medium, under an inert atmosphere and in the presence of a catalyst, which monomer will then polymerize under these reaction conditions.

A
20- ~~Pharmaceutical composition containing at least one active ingredient and, as an inert support or excipient, at least one cross-linked copolymer according to one of claims 1 to 13.~~

A
10 21- ~~Pharmaceutical composition containing at least one active ingredient and, as an inert support or excipient, at least one copolymer according to one of claims 14 to 16.~~

22- Use of a pharmaceutical composition according to one of claims 20 to 21 for sustained release.

15 23- Use of a pharmaceutical composition according to one of claims 20 to 21 as a bioadhesive pharmaceutical system.

24- Use of a pharmaceutical composition according to claim 21 for the specific release of the active ingredient at the level of the colon.

25- Use according to claim 24 to convey the active ingredient intended for the treatment of diseases of the colon.

20 26- Use according to claim 24 to convey the active ingredient which is absorbed at the level of the colon.

27- Use according to claim 24 to convey the active ingredient which is degraded in the upper parts of the digestive tract.

209220748268001